Agenda

Virtual Pharma CI EUR on March 19, In-Person Pharma CI EUR November 5-6

We know how important the Pharma CI Europe conference is to you and your business. As we have grappled with the effect of the Covid-19 coronavirus outbreak on event plans, we have held two principles uppermost in our mind: the health and safety of all attendees, and the high-value experience you count on. Given the recent declaration by the Swiss government to ban all large public events, we believe it is not prudent to go forward with our traditional conference this spring. We are pursuing an alternative approach to provide the benefits you expect across several formats.

Expanded Event Formats
1. We will convene a live Pharma CI Europe Conference in Zurich on November 5-6 at the same venue. This is confirmed so you can adjust travel plans accordingly.
2. We will also convene on March 19 a virtual Pharma CI Conference in webinar format. We will share more details on the webinar program soon.

The coronavirus challenge is unprecedented for us in our decade of serving CI professionals. We want our CI community to thrive, so even as we are prioritizing health by avoiding a large in-person gathering at this time, we are excited to provide new ways for you to share expertise and enhance interaction this month and beyond.

All the best,
The Pharma CI Conference Team

MASTERCLASS WORKSHOPS
Wednesday, 4 November, 2020
CONFERENCE DAY 1
Thursday, 5 November, 2020
CONFERENCE DAY 2
Friday, 6 November, 2020

Registration & Light Networking Breakfast

Developing a Competitive Activity Framework to Enhance Organizational Competitiveness

This workshop session (with breakouts), will give participants first-hand insights from a combined 30+ years of experience in delivering strategic and tactical workshop-style solutions, using an optimal blend of established CI frameworks alongside INOVIS’ in-house proprietary methodologies.

Key to this session will be addressing business needs across the lifecycle, whereby participants will:

* Develop an in-depth understanding of how a diverse range of facilitated activities (Rapid Immersion, Threat Assessment and Competitor Simulations) can help deliver strategic and competitive insights within an organization
* Appreciate the importance of leveraging the outcomes of workshops to inform and direct decision making
* Receive hands-on opportunities to apply learnings to a pharma case-study in a learning environment
Using business case studies, real-life experiences and validated theory, the INOVIS team will equip you with a number of go-to techniques that can be rapidly integrated into ongoing CI Practice, whether you’re a seasoned CI professional veteran, or newer to the field.

Presented by INOVIS

Networking Lunch

Best Practices to Create / Write Effective and Impactful CI Reports and Presentations

An “art” and “science” exists when considering clear, concise and actionable competitive strategy report writing in the biopharmaceutical space.

Many biopharma CI reports disseminated by the Agency are overly verbose, high-level and lack the substantive actionability required for internal usage – facilitating a seamless cascade to management & leadership.

Today’s workshop will translate classical stylistic business writing techniques including those of Strunk and White to the 21st-century biopharmaceutical CI and Strategy world.

In this workshop, we will facilitate two (2) breakouts during which “raw intelligence learnings” will be synthesized and translated into actionable CI deliverables using PowerPoint writing skills and infographic design techniques.

This Workshop is facilitated by David Alderman, President of Molekule Consulting, a global competitive intelligence and strategy consultancy dedicated to the life sciences and biopharmaceutical verticals. David has deep experience from early-development to late-lifecycle management and beyond within biopharma across the competitive landscape among myriad therapy areas, players and subject matters. David is a Subject Matter Expert on the biopharmaceutical vertical; with a particular focus on competition within branded biopharma, small molecule generics and biosimilars.

Presented by Molekule Consulting

Networking Break and Refreshments

Leveraging Value-Added Services to Drive Profitable Growth in International Markets

The vast majority of pharma companies are not successful in using value-added services to drive profitable growth in price-constrained international markets. Insights has a critical role to play in profiling patients/providers/patients, understanding their requirements, and creating a plan to price to value.

Presented by DuckerFrontier

Masterclasses/Workshops Conclude

Good Morning! Registration & Light Networking Breakfast in Exhibition Hall

Chairpersons’ Opening Remarks

Presented by Novartis

Keynote: Can a Transformational Product Transform Market Adoption?

Every category has certain adoption dynamics driven by the previously recently launched products in the category.

When faced with a new product that can be transformational to the field, the key issue becomes understanding the adoption dynamics, identifying the drivers of change within this dynamic, and then building a plan to deliver on transforming the adoption cycle.

Presented by Arvelle Therapeutics

How to Build a Successful and Sustainable CI Function

Daniel will share with the audience his learnings and experiences in building and leading successfully several CI teams over a time span of more than 20 years in the industry.

Topics we will cover:
• What are the 10 “commandments” to build a successful CI team
• What is needed to make the CI team relevant and impactful for a company
• How to recruit the best CI talent into the department and retain them

The audience can expect to be able to participate actively in the “conversation” and contribute to the program.

Presented by Molekule Consulting

Refresh & Connect in Exhibition Hall

“Ask the Experts” Interactive Breakout Groups: Choose 1 of 4, and these plus more breakout groups will be presented again tomorrow

(Explore and capture the power of participants’ insights and experiences. Delve into these topics in this fun and informal environment in intimate groups.)
BREAKOUT 1
More Effectively Collaborate With Your Colleagues and Agencies to Drive Enhanced CI and Business Planning at Your Company

Presented by Bayer

BREAKOUT 2
Beyond “Usual” Intelligence on Medicinal Products: How to Monitor Digital Scenario

Presented by Chiesi Farmaceutici S.p.A.

BREAKOUT 3
Personal Professional Challenges – How to Sell your Analysis Internally

Presented by SOTIO, a.s.

BREAKOUT 4
How to Best Track Generics Entering the Market

Presented by Janssen

Networking Luncheon

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

Lessons From Inside Novartis, Roche, and Atacana - 5 Questions You Need to Ask to Maximize Your Success and Significantly Increase the Value of Your Competitive Intelligence

Many CI professionals fail to understand that the perceived value of their CI work is the basis for their career success. Still, others fail to realize that they must translate the importance of their insights into long-term gains for the stakeholders in the stakeholders' perception.

One of pharma’s most successful CI professionals reveals 5 questions you must ask at the beginning of each project to ensure:

1. A dramatic return on investment for your CI efforts
2. Be recognized for the impact you are creating in your organization
3. Increase your resources and get your next promotion

In this presentation, Salvador Carlucci clearly demonstrates how CI professionals can educate their stakeholders on how to determine the real value of competitive intelligence and how to capture that value to propel their career. Filled with inspirational stories and practical advice, make sure not to miss this presentation.

Presented by Atacana Group

SESSION TWO

Managing Future Competitive Risk in R&D: An ML Based Approach to Understand the Drivers of Success & Failure

Presented by Evaluate

Helping pharma companies understand competitive risk in R&D using Product Specific Probability of Approval (PTRS). Learnings taken from utilising unbiased and transparent Machine Learning approach in understanding drug success and failure drivers.

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

10 Lessons from a CI Life

Marjorie Norman has seen a lot of changes over the past 25 years as a CI professional in both industry and consultancy. However, some basic truths still hold strong. This session will address Marjorie’s experience - the good, the bad and the ugly - in developing and maintaining a best-in-class CI program.

Presented by Cambridge Healthcare Research

SESSION TWO

The Art of Primary Intelligence

If you are new to competitive intelligence or just not sure of what primary intelligence gathering really is, this is the opportunity to gain an overview of the skills and techniques used by primary Intelligence experts.

With over 30 years at the “sharp-end” of intelligence gathering across the world, one the Co-Founder(s) of Dig Worldwide will provide plenty of real-life anecdotes and experiences. Dig Worldwide’s talk will briefly cover the following:
• Legal and ethical frameworks
• The six techniques that aid competitor-based communications
• Suggestions on how to protect your competitive advantage in the office and other public venues from companies such as Dig Worldwide

Presented by Dig Worldwide

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

Challenges in Rare Disease

Presented by Alnylam Pharmaceuticals

SESSION TWO

What Winners Do - Cracking the Code of Sales Force Deployment in Medical Devices

Presented by Johnson & Johnson

Refuel & Rejuvenate in Exhibition Hall

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

Using CI to Predict Approval Timelines in EU

This session will give practical insights and direction on how CI can be leveraged to predict approval timelines for drug applications in Europe.

The EMA follows various procedural timetables to evaluate potential marketing authorisations, which differ in length and requirements from the US FDA and other agencies. We will present data to help you more accurately predict approval timelines and discuss how this can be supplemented by CI insights to better understand competitors’ launch strategy.

Presented by Lifescience Dynamics

SESSION TWO

TBA

Presented by Vifor Pharma

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

Insights Triangulation

Presented by Ipsen

SESSION TWO

How to Measure Impact on your Organization

Presented by Galderma

Cocktail Reception and Networking

Good Morning! Registration & Light Networking Breakfast in Exhibition Hall

Chairpersons’ Opening Remarks

Presented by Novartis

Keynote: Megatrends in Healthcare

This talk will discuss the interplay of various factors that are currently influencing the healthcare and pharmaceutical landscapes and the emerging trends that are shaping the new era of healthcare.

How can we use demographic shifts to help inform new business models? How will digital disruption affect drug development and access? How are mHealth platforms shifting patients’ approaches to healthcare?

Presented by Lifescience Dynamics

Keynote: Late Life Cycle Management (LLCM): The Strategic Value of Generic & Biosimilar CI In Life Sciences

This session will provide insights and highlight best practices to enable LLCM value and asset maximization by leveraging a number of tools unique to CI professionals.

Specifically this presentation will enable you to:

* Advance your understanding of core Gx/biosimilar market dynamics and corresponding CI solutions
* Set up a best-in-industry Gx/biosimilar regulatory intelligence (RI) and CI tracking program
* Understand Gx / biosimilar product development and entry strategies
* Identify potential actions to optimize launches

Presented by INOVIS

Refuel & Rejuvenate in Exhibition Hall

“Ask the Experts” Interactive Breakout Groups: Choose 1 of 4

(Explore and capture the power of participants’ insights and experiences. Delve into these topics in this fun and informal environment in intimate groups.)
BREAKOUT 1
More Effectively Collaborate With Your Colleagues and Agencies to Drive Enhanced CI and Business Planning at Your Company

Presented by Bayer

BREAKOUT 2
Beyond “Usual” Intelligence on Medicinal Products: How to Monitor Digital Scenario

Presented by Chiesi Farmaceutici S.p.A.

BREAKOUT 3
Personal Professional Challenges – How to Sell your Analysis Internally

Presented by SOTIO, a.s.

BREAKOUT 4
Monitoring of Digital Health Trends (Portals, Data Sources)

Presented by Janssen

Networking Luncheon

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

How to Use Purchase Decision Maker Insights to Drive Strategic Decisions

Key purchase decision makers of Life science (LS) products are generally have different buying decision criteria than the actual end users. This creates a disconnect between the LS product value proposition of the key decision maker and that of the end user.

A result of this can be dissatisfied end users and low utilization rates. Understanding the value proposition disconnect and developing strategies to better align the two value propositions can improve both patient and sales outcomes.

This session will describe how Win/Loss for the LS market can generate new insights into intermediate and end user decision factors and demonstrate how to adjust the value proposition to improve the match for both end user and purchase decision maker. With a particular emphasis on drug formulary, delivery systems, surgical devices, and medical imaging products, the session will discuss how to design a Win/Loss program for LS, how to interpret Win/Loss findings for strategy development, and how a Win/Loss program of LS differs from typical Win/Loss programs.
Session attendees will gain a deeper understanding of how Win/Loss can apply to LS and drive strategy. Real world (blinded) examples of Win/Loss components (questionnaires, interview excerpts, and analysis reports) will be presented to illustrate the different tools and benefits of a Win/Loss program.

Presented by Fletcher/CSI

SESSION TWO

Emerging Trends within the Biopharma Industry: The Evolution of Challenges and Rising Opportunities

Are there untapped opportunities within the biopharma industry? Prescient has noticed a high volume of changes and vast opportunities for success in developing markets and technologies.

If biopharma companies want to expand in these emerging areas, their strategy must be tailored to the developing pace of change. We will discuss the most promising emerging areas, to lay out the opportunities, challenges and trends that will drive change and explain how CI can help steer organizational strategic success.

Presented by Prescient Healthcare Group

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

Adapting Predictive Analytics in an Organization to Gain Competitive Edge

Presented by Lonza

SESSION TWO

Tracking and Reacting to the Changing Landscape of External Innovation

Presented by Limbach Gruppe

Refuel & Rejuvenate in Exhibition Hall

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

When CI goes Global: a 10 Year Journey to Bring Intelligence at Global Level

Presented by Chiesi Farmaceutici S.p.A.

SESSION TWO

Business Case – When to Prepare It, What Shall Be In, What Is the Impact of CI and MR on Business Case Outcome and How to Communicate It to Decision Makers

Presented by Tillotts Pharma

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT SESSIONS

SESSION ONE

How Strategic/Competitive Intelligence Can Significantly Inform a Company’s Strategy – Preclinical to Clinical Development, to Impact on BD/Out-Licensing/Collaboration Efforts

Presented by Redx Pharma

SESSION TWO

Designing Winning Trials for Reimbursement – Strategic Framework

Presented by Novartis

Closing Remarks from Co-Chairs

Conference Concludes